Indeed, the ZUMA-1 (Long-Term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma) trial and TRANSCEND (Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma) trials have not been regraded by an expert panel paying special attention to attribution and causation of NT. 7 0 obj Minor (1)acetazolamide will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Assessed using Balis scale; Grade 2. nci toxicity grading scale for brentuximabgriffin park demolishedgriffin park demolished 0
Adjust dosage of CYP3A4 substrates, if clinically indicated. Epub 2015 Mar 19. <>/OutputIntents[<>] /Metadata 1286 0 R>>
is employed by the Analysis Group, which received research funding from Novartis. Epub 2015 May 12. Modify Therapy/Monitor Closely. posaconazole increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's ]KAyQYi!8w;hb N4T'ea=AHU !YlmNv,94c4. .
Solved a patient receiveing an initial brentuximab infusion - Chegg Self-care ADL refers to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not being bedridden. phenobarbital decreases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. this drug, research results, and ongoing clinical trials. is employed by Novartis. Vital signs were stable, with a temperature of 36.9C, pulse 84, respirations of 20, and blood pressure of 107/67 mm Hg. Monitor Closely (2)elagolix will increase the level or effect of brentuximab vedotin by P-glycoprotein (MDR1) efflux transporter. Monitor Closely (2)stiripentol, brentuximab vedotin. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Please see your health care professional for more information about your specific medical condition and the use of this drug. Modify Therapy/Monitor Closely. In the JULIET trial, NT was graded, per protocol, using CTCAE v4.03 criteria (Table 1). Monitor Closely (1)dexamethasone decreases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Acute infusion reaction management and subsequent premedication strategies are outlined. Symptoms that occurred up to 1 year after infusion were considered. For the present retrospective analysis, NT patient-level data from case report forms were collected for the JULIET trial for the 9-month data cutoff of December 2017. Modify Therapy/Monitor Closely. brentuximab vedotin decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. . . -, Uzel I., Ozguroglu M., Uzel B., et al. <>stream Monitor Closely (1)trastuzumab, brentuximab vedotin. and transmitted securely. Use Caution/Monitor. dexamethasone decreases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Clinical Cancer Research. Monitor or titrate P-gp substrate dose if coadministered. Use Caution/Monitor. enzalutamide will decrease the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)fosamprenavir increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Severe Acute Pulmonary Toxicity Associated with Brentuximab in a Patient with Refractory Hodgkin's Lymphoma Severe Acute Pulmonary Toxicity Associated with Brentuximab in a Patient with Refractory Hodgkin's Lymphoma Case Rep Pulmonol. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. Monitor Closely (1)enzalutamide will decrease the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. . Monitor patients for adverse reactions. Monitor Closely (1)posaconazole increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.
Brentuximab Vedotin - NCI - National Cancer Institute . Minor/Significance Unknown. Use Caution/Monitor. Authors Fexinidazole inhibits CYP3A4. Monitor Closely (1)nefazodone increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor patients for adverse reactions. NCI Common Terminology Criteria for Adverse Events (CTCAE) data files and related documents are published here. c_MGq|,`Y8vyD;L}v~@$\OpW2[[ZnFp4`q`/&MbzDBJ:*Y!0J-Xy>VYp{ iAT=`5"u.'wrZ(`E5Qm='X:i6|2{h=[^?aK$#!;N%CljIb`5J2uX6; Avoid or Use Alternate Drug. Blood Adv 2020; 4 (7): 14401447. Monitor Closely (1)ketoconazole increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Patients with primary mediastinal B-cell lymphoma were not eligible for enrollment. <>stream Would you like email updates of new search results? East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018, Cytokine release syndrome with the novel treatments of acute lymphoblastic leukemia: pathophysiology, prevention, and treatment, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkins lymphoma: a systemic review and meta-analysis, Correlative analyses of cytokine release syndrome and neurological events in tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma patients. Use Caution/Monitor.
PDF Get to the Bottom of Lab Toxicity Grading: Challenges and Most Use Caution/Monitor. V.V.R.
Do not drive, use machinery, or do anything that needs alertness until you can do it safely. Modify Therapy/Monitor Closely. Monitor Closely (1)berotralstat will increase the level or effect of brentuximab vedotin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Q4|o<9RIG"q\b1JEK["O|{Qt2{GgW5HRN~qk+#G$+ Iyao"s7]pUBj" Monitor patients for adverse reactions. A grading (severity) scale is provided for each AE term. Regrade of JULIET trial patient-level data showed 50 patients as having any-grade NT by CTCAE, 19 patients by mCRES, and 19 patients by ASTCT criteria. This scale was then grouped with gradation of signs of increased intracranial pressure and presence of seizures, whereby the greatest level of toxicity in any given domain would also be captured as the overall CRES grade. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine. Regrade of JULIET trial patient-level data showed 64 patients as having any-grade CRS by Penn scale, 63 patients by Lee scale, and 61 patients by ASTCT criteria. (B) Cross-classification of NT by 3 grading scales: CTCAE, ASTCT, and mCRES. Minor (1)anastrozole will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma. Talk to your doctor if you are using marijuana (cannabis).Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Older adults may be more sensitive to the side effects of this drug.Tell your doctor if you are pregnant or plan to become pregnant. This medication is given in a hospital or clinic and will not be stored at home. (A) Classification of NT by CTCAE, mCRES, and ASTCT grading systems (N = 111). Abstract 254, Kite announces two-year data for Yescarta, Juno Therapeutics reports clinical hold on the JCAR015 phase II ROCKET trial [press release]. This drug is available at the lowest co-pay. (a) Computed tomography (CT) of the chest showing patchy, nodular ground glass opacities, MeSH Minor (1)cyclophosphamide will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
If not feasible, avoid use of abametapir. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Lancet Oncol. . . Peripheral T-cell lymphoma that has the CD30 protein. Intraveous granisetron was given for nausea. Tremors and myoclonus associated with immune effector cell therapies may be graded according to CTCAE v5.0, but they do not influence ICANS grading. Use Caution/Monitor. 2018 Oct;5(10):e450-e461. hN0W7|sRC%*;gUg|Ib(I
L!B$R,=$|=I[TbF[@z`H)n7}Q,iz8O/KZG. Recognizing that the CAR-T-associated NT represents a unique syndrome that would benefit from a unified scale, the multiinstitution CAR-T cell-therapy-associated Toxicity (CARTOX) Working Group introduced the term CAR-T cell-Related Encephalopathy Syndrome (CRES).23 The CARTOX group created a CRES grading system that included a 10-point questionnaire (CARTOX-10), designed to capture subtle to severe cognitive and attentive dysfunction. . Coadministration of efgartigimod with medications that bind to the human neonatal Fc receptor may lower systemic exposures and effectiveness of such medications.
Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration.
PDF Common Terminology Criteria for Adverse Events v3.0 (CTCAE) 0000004401 00000 n
This page contains brief information about brentuximab vedotin Presented at 24th Congress of the European Hematology Association; 13-16 June 2019; Amsterdam, The Netherlands. It may be graded according to CTCAE v5.0. 1 b. Components and Organization CATEGORY A CATEGORY is a broad classification of AEs based on anatomy and/or pathophysiology. . Monitor Closely (1)lopinavir increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Please confirm that you would like to log out of Medscape. This analysis had 2 objectives. is employed by the Analysis Group, which received funding from Novartis. received honoraria, membership on the board of directors or advisory committees, and research funding from Novartis; consultancy and honoraria from CRSPR Therapeutics, Incyte, and Juno Therapeutics; honoraria from Kite Therapeutics; patents and royalties from Athersys, Inc.; and is employed by Oregon Health & Science University. Minor/Significance Unknown. Monitor patients for adverse reactions. 0000005575 00000 n
0000004470 00000 n
2015;385(9980):18531862. An official website of the United States government. The brentuximab vedotin was restarted 30 minutes after symptom resolution at a decreased infusion rate to be administered over 60 minutes. A New First-line Regimen for Advanced Hodgkin Lymphoma? https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcvYWRjZXRyaXMtYnJlbnR1eGltYWItdmVkb3Rpbi05OTk2ODA=, View explanations for tiers and Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates. Use Caution/Monitor. Use Caution/Monitor. Expert Rev Hematol. Upon the emergence of these symptoms, the brentuximab vedotin infusion was held. Initial staging revealed lymphadenopathy above and below the diaphragm, as well as fluorodeoxyglucose (FDG)-avid lung lesions, splenic lesions, and multiple sites of bony involvement. brentuximab vedotin decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. You should not become pregnant while using brentuximab. Use Caution/Monitor. The numbers inside of the columns refer to absolute number of patients. berotralstat will increase the level or effect of brentuximab vedotin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Avoid or Use Alternate Drug. 131 0 obj<>stream
Adjust dose according to prescribing information if needed. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents. NT by ASTCT criteria provided concordance for 34 patients, a lower grade for 31 patients, and a higher grade for 3 patients compared with the CTCAE scale (Figure 1B). To lower your risk, your doctor may add a medication and tell you to drink plenty of fluids. Monitor Closely (1)carbamazepine decreases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. In this version, toxicity grading was based on absolute ranges relative to the upper and lower limits of normal. Only 2 of the 31 patients who had NT per CTCAE, but grade 0 NT by mCRES and ASTCT, had received corticosteroids (Table 4). Monitor Closely (1)encorafenib, brentuximab vedotin. Severe infusion reactions to brentuximab vedotin in two patients with Hodgkin lymphoma previously treated with allogeneic stem cell transplantation. Contraindicated (1)brentuximab vedotin and bleomycin both increase Other (see comment). In the JULIET trial, NT was identified and graded per protocol according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.03.10 Because it was not designed specifically for CAR-T cell therapy trials, the CTCAE scale has shortcomings in accurately capturing the severity, timing, and spectrum of NT. received honoraria, membership on the board of directors or advisory committees, and research funding from Celgene; consultancy and honoraria from Dava Oncology; honoraria and research funding from Genentech; membership on the board of directors or advisory committees for Gilead; consultancy, honoraria, and research funding from Merck; honoraria, membership on the board of directors or advisory committees, and research funding from Novartis; and consultancy, honoraria, and membership on the board of directors or advisory committees for Nordic Nanovector. Version 1.2019. Lancet (London, England) 2015;385:18531862. Brentuximab may harm an unborn baby. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. Novartis is committed to sharing with qualified external researchers access to patient-level data and supporting clinical documents from eligible studies. Serious - Use Alternative (1)lonafarnib will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. This study is the first to retrospectively apply a modified version of the CARTOX Working Groups CRES grading system and the ASTCT consensus ICANS criteria to the same CAR-T cell-related NT data set from a registrational trial. The most current release files are in order of appearance: CTCAE_5.0; CTCAE v5.0 in the NCI Thesaurus .xlsx format; CTCAE v5.0 in the NCI Thesaurus .xls format; CTCAE v5.0 in the original CTEP .xlsx format Indicated for primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30 expressing mycosis fungoides (MF) who have received prior systemic therapy, 1.8 mg/kg IV q3Weeks; not to exceed 180 mg/dose, Continue until a maximum of 16 cycles, disease progression, or unacceptable toxicity, Indicated in previously untreated CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP), 1.8 mg/kg IV q3Weeks for 6-8 doses; not to exceed 180 mg/dose, Patients weighing >100 kg should be calculated based on a weight of 100 kg, Indicated in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide (AVEPC), for previously untreated high risk classical Hodgkin lymphoma (cHL) in pediatric patients aged 2 years, Day 1: Brentuximab 1.8 mg/mg (not to exceed 180 mg/dose) IV with each cycle of chemotherapy for up to 5 doses, Calculate patients weighing >100 kg based on a weight of 100 kg. %%EOF
% Search for other works by this author on: Chimeric antigen receptor-T cell therapy: Practical considerations for implementation in Europe, CAR T cell immunotherapy for human cancer, Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial, Analysis of safety data from 2 multicenter trials of CTL019 in pediatric and young adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Antineoplastics, Anti-CD30 Monoclonal Antibodies. also provided consultant services to and received payment from Novartis.
Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments. 0000001503 00000 n
Serious - Use Alternative (1)voxelotor will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. 0000000016 00000 n
Madrid, Spain, Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia, Building blocks for institutional preparation of CTL019 delivery, Impact of disease burden on long-term outcome of 19-28z CAR modified T cells in adult patients with relapsed B-ALL [abstract], Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia, Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma, NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas. Avoid coadministration with sensitive CYP3A substrates. A simplified grading scale derived from the CTCAE was also created. Delayed onset bleomycin-induced pneumonitis. . Epub 2013 Nov 15. 2015 Aug;8(4):403-12. doi: 10.1586/17474086.2015.1044432. Avoid or Use Alternate Drug.
The site is secure. No grade 5 CRS or NT events occurred. Monitor patients for adverse reactions. (A) Frequency of CRS event grades by the Penn, Lee, and ASTCT grading scales (N = 111). Monitor patients for adverse reactions. The investigators thank the patients, their families, and the clinical study teams who participated in the JULIET trial. th{U j06,`A & NW`c-D&2,s;H$2DD;IXDjzRirTz6>XjNHWa][+RpVR=} \ShV*IQ_O|YAiBXvlX5y,seqHi|@h(cg="b&XY"im|%{7s\fI5I5FMi^Zqickfk,;n+{!iv
|z$85w~#e Prevention and Treatment of Side Effects of Immunotherapy for Bladder Cancer. HOW TO USE: This medication is given by injection into a vein over 30 minutes by a health care professional. Consider reducing the dose of P-glycoprotein (P-gp) substrates, if adverse reactions are experienced when administered concomitantly with stiripentol. Comment: Palifermin should not be administered within 24 hr before, during infusion of, or within 24 hr after administration of antineoplastic agents. ketoconazole increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.elagolix will decrease the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Common terminology criteria for adverse events - UpToDate View the formulary and any restrictions for each plan. USES: Brentuximab is used to treat certain types of cancers (Hodgkin's lymphoma, systemic anaplastic large cell lymphoma, peripheral T-cell lymphoma, primary cutaneous anaplastic large cell lymphoma, CD30-expressing mycosis fungoides). Instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the telephone, managing money, and so on. Use Caution/Monitor. Monitor Closely (1)brentuximab vedotin decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. restrictions. };wN:iyUFYg,Wyi^dgvBMu9L> {Ij{>i JS8Lk6P&adAQWEPN_aKe7+S|O[u/_>v~?W I}yr>T%D$D5fqYsms
xp
`sv@K4([MhT3O Talk to your doctor if you have been exposed to an infection or for more details.Tell your health care professional that you are using brentuximab before having any immunizations/vaccinations. }? cenobamate will decrease the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Copyright(c) 2023 First Databank, Inc. Adjust dose of drugs that are CYP3A4 substrates as necessary. eslicarbazepine acetate will decrease the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Urology. Using a diffuse and overlapping variety of CTCAE NT terms can create confusion, misreporting, and suboptimal clinical management of NT associated with CAR-T cell therapy. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. provided study materials or patients; V.V.R. Bethesda, MD 20894, Web Policies We retrospectively assessed differences and concordance among 3 available grading scales (the National Cancer Institute Common Terminology Criteria for Adverse Events v4.03 [CTCAE], modified CAR-T Related Encephalopathy Syndrome [mCRES], and American Society for Transplantation and Cellular Therapy [ASTCT] scales) applied to the same set of NT data from the JULIET (A Phase 2, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory DLBCL) trial. Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, Huebner D, Ansell SM. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered. The first dose of brentuximab vedotin was administered without difficulty, at full dose (1.8 mg/kg) at a standard infusion time of 30 minutes. 0000003265 00000 n
Monitor Closely (1)ribociclib will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. unspecified interaction mechanism. In the subgroup analysis of patients with or without CRS, all 3 grading systems identified more patients with CRS as having NT compared with patients without CRS (Table 6). All patients with fever in the setting of chemotherapy-induced neutropenia require immediate medical attention regardless of the toxicity grade. If use is unavoidable, refer to the prescribing information of the P-gp substrate for dosage modifications. The National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE), version 4.0, and the Total Neuropathy Score clinical version (TNSc) are both validated scores to quantify peripheral neuropathy (PN), with the TNSc being more sensitive to clinical changes. (A) Classification of NT by CTCAE, mCRES, and ASTCT grading systems (N = 111). Monitor Closely (1)imatinib increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Journal of the National Comprehensive Cancer Network : JNCCN. Please enable it to take advantage of the complete set of features! Richard T. Maziarz, Stephen J. Schuster, Vadim V. Romanov, Elisha S. Rusch, Junlong Li, James E. Signorovitch, David G. Maloney, Frederick L. Locke; Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial. Monitor Closely (1)mifepristone will increase the level or effect of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Lancet. Use Caution/Monitor. |n9>S[JRpN}O%N^W`kV7b]v:!E"}e"7-3h8B5Sp?ZA
%ET89" baH& This regimen was chosen based on the clinical rationale for H1 and H2 blockade, as well as corticosteroid and antipyretic coverage, in the prevention of hypersensitivity reactions, not classified as anaphylaxis. { @,dBm2L:XKolLvYYAo8B.cCe/N : . stiripentol will increase the level or effect of brentuximab vedotin by P-glycoprotein (MDR1) efflux transporter. Monitor Closely (1)itraconazole increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Consider reducing the dose of P-glycoprotein (P-gp) substrates, if adverse reactions are experienced when administered concomitantly with stiripentol. government site. Patients treated with selinexor may experience neurological toxicities. 0000009670 00000 n
After reconstitution (see section 6.6), each mL contains 5 mg of brentuximab vedotin.
D Wayne Lukas Grandchildren,
Johnny Hunt Testimony,
Articles N